Recombinant M. bovis BCG expressing the PLD protein promotes survival in mice challenged with a C. pseudotuberculosis virulent strain

Publication date: 14 June 2018
Source:Vaccine, Volume 36, Issue 25
Author(s): Karen Silva Leal, Mara Thais de Oliveira Silva, Andréa de Fátima Silva Rezende, Francisco Silvestre Brilhante Bezerra, Karine Begnini, Fabiana Seixas, Tiago Collares, Odir Dellagostin, Ricardo Wagner Portela, Vasco Ariston de Carvalho Azevedo, Sibele Borsuk
The aim of this study was to evaluate the survival of mice inoculated with M. bovis BCG Pasteur recombinant expressing the PLD protein and challenged with a C. pseudotuberculosis virulent strain. Four groups were immunized with a sterile 0.9% saline solution (G1), 10⁶ CFU of M. bovis BCG Pasteur (G2), 10⁶ CFU of M. bovis BCG/pld (G3) or 10⁶ CFU of M. bovis BCG/pld with a booster with rPLD (G4) and challenged with 10⁴ CFU of C. pseudotuberculosis MIC–6 strain. The highest survival rate of 88% was observed in G4, followed by 77% in G3 and 66% in G2. A significant statistical difference was observed in the levels of cytokines IFN-γ and IL-10 in vaccinated groups (G3 and G4) when compared with the control group (G1) (p < 0.05). The results seem promising as the recombinant vaccine elicited a cellular immune response and provided significant survival after a high virulent challenge.



https://ift.tt/2IOiu5I